Discovery of Novel DPP-IV Inhibitors as Potential Candidates for the Treatment of Type 2 Diabetes Mellitus Predicted by 3D QSAR Pharmacophore Models, Molecular Docking and De Novo Evolution

Dipeptidyl peptidase-IV (DPP-IV) rapidly breaks down the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). Thus, the use of DPP-IV inhibitors to retard the degradation of endogenous GLP-1 is a possible mode of therapy correcting the defect in incre...

Descripción completa

Detalles Bibliográficos
Autores principales: Musoev, Azizullo, Numonov, Sodik, You, Zhuhong, Gao, Hongwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6720998/
https://www.ncbi.nlm.nih.gov/pubmed/31394858
http://dx.doi.org/10.3390/molecules24162870

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6720998/
https://www.ncbi.nlm.nih.gov/pubmed/31394858
http://dx.doi.org/10.3390/molecules24162870

Ejemplares similares